Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma Inc. (NASDAQ: LTRN) has initiated the Phase 2 Harmonic™ clinical trial, dosing the first patient with its investigational drug LP-300 in combination with chemotherapy for never smokers with advanced non-small cell lung cancer (NSCLC). The trial aims to assess the overall and progression-free survival in 90 patients, with 60 receiving LP-300 and 30 on standard chemotherapy. Previous trials showed a 91% overall survival rate at two years for LP-300 patients compared to those on chemotherapy alone. The market potential for this demographic is estimated between $1.5 to $2.0 billion.
Lantern Pharma Inc. (NASDAQ: LTRN), a biopharmaceutical company utilizing its RADR® AI platform for oncology drug development, announced presentations at three upcoming events. CEO Panna Sharma will present on March 22 at the Rare Disease Innovation & Partnership Summit in Philadelphia, discussing AI in drug development. He will also participate in a free webinar on March 23, co-hosted by Science History Institute and American Chemical Society, focusing on AI's impact on drug discovery. Additionally, Peter Carr will moderate a session at the Genomics in Precision Oncology Xchange on April 5 in Boston, emphasizing clinical trial design.
For more information, visit www.lanternpharma.com.
Lantern Pharma (NASDAQ: LTRN) announced significant operational highlights and financial results for the fourth quarter and fiscal year 2022. The Harmonic™ clinical trial for never-smoker patients with non-small cell lung cancer (NSCLC) has activated 5 clinical sites across 12 locations, with patient enrollment expected in Q2 2023. The company also completed IND-enabling studies for drug candidates LP-184 and LP-284, with IND submissions planned for April and mid-2023, respectively. Lantern reported a cash position of
Lantern Pharma Inc. (NASDAQ: LTRN) announced its participation in the AACR Annual Meeting from April 14-19, 2023 in Orlando, FL. The company will present a poster titled LP-184, an acylfulvene class small molecule therapeutic, focusing on its synthetic lethality mechanism targeting DNA damage repair deficient cancers, affecting 25-30% of solid tumors. The presentation is scheduled for April 19, 2023, 9:00 a.m. – 12:30 p.m. ET. Lantern aims to advance LP-184 to a Phase 1 clinical trial by mid-2023. Additionally, a webinar on synthetic lethality will be held on March 21, 2023 featuring expert Zoltan Szallasi.
Lantern Pharma Inc. (NASDAQ: LTRN) announced a webcast on March 20, 2023, at 4:30 p.m. ET, to disclose its fourth quarter and fiscal year 2022 financial results. Management, led by CEO Panna Sharma, will discuss operating and financial metrics for the fiscal year ended December 31, 2022 and outline upcoming milestones. Lantern Pharma is focused on oncology and leverages its proprietary RADR® AI platform to enhance drug discovery methods.
A replay will be available post-call on their investor relations website.
Lantern Pharma Inc. (NASDAQ: LTRN) announced that it has no exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank, ensuring its financial stability. The company’s cash, cash equivalents, and marketable securities are managed through top-tier financial institutions, providing sufficient resources to support operations and development through 2025. Lantern Pharma utilizes its proprietary RADR® AI platform to enhance oncology drug discovery, focusing on genomic profiling to identify patients likely to benefit from its therapeutics. This strategic approach aims to improve treatment outcomes for cancer patients.
Lantern Pharma (NASDAQ: LTRN) announced new findings supporting the development of LP-100 combined with PARP inhibitors for treating metastatic prostate cancer and other indications. Synergistic effects were observed in studies using LP-100 alongside notable PARP agents like Olaparib. Preliminary Phase 2 trial data indicated a median overall survival of 12.5 months for nine patients in Denmark, better than comparable treatment regimens. Future market potential for LP-100 is estimated between $700 million and $2 billion. This strategic focus aims to maximize LP-100's market opportunities while enhancing treatment pathways for patients with specific gene mutations.
Lantern Pharma (NASDAQ: LTRN) will host a virtual key opinion leader (KOL) webinar on March 21, 2023, at 12:00 p.m. ET, focusing on synthetic lethality in oncology. Dr. Zoltan Szallasi, a prominent expert, will discuss the mechanism of action behind Lantern's drug candidate LP-184 and its implications for solid tumors. Attendees will learn about the history of synthetic lethality, how it targets DNA damage repair deficiencies, and LP-184's potential to enhance cancer treatments. Registration is available here. A replay will be accessible on Lantern's website following the event.
Lantern Pharma (NASDAQ: LTRN) announces the formation of a wholly-owned subsidiary, Starlight Therapeutics, focused on developing therapies for CNS and brain cancers. Leveraging the RADR® AI platform, Starlight's lead candidate, STAR-001, shows promising results in in-vitro and in-vivo studies, demonstrating blood-brain barrier permeability and nanomolar potency. Clinical trials are expected in late 2023 and early 2024 for indications with over 500,000 new cases annually and a market potential exceeding
Lantern Pharma (NASDAQ: LTRN) has expanded its clinical development team, appointing Dr. Reggie Ewesuedo as Vice President of Clinical Development. This strategic move aims to advance the ongoing Harmonic™ trial for non-small cell lung cancer (NSCLC) and initiate first-in-human Phase 1 trials for drug candidates LP-184 and LP-284, projected to launch in mid-2023. Dr. Ewesuedo brings over 20 years of experience in drug development, enhancing the company's capabilities in oncology. The team also welcomes Ernest Kitt as Head of Clinical Operations and other professionals to bolster their clinical efforts.